…
QHSLab, Inc., a medical device technology and software-as-a-service (SaaS) company, provides tools to evaluate and treat chronic disease and preventive care through reimbursable procedures. The company focuses on value-based healthcare, informatics, and algorithmic personalized medicine, including digital therapeutics, behavior based remote patient monitoring, and chronic care and preventive medicine. Its digital healthcare and clinical decision support and point of care solutions also support non face to face remote patient and therapeutic monitoring, address chronic care, and preventive medicine. The company provides quality health system lab expert system (QHSLab), designed to function as an extension of a medical practice's existing clinical workflow that supports structured screening, automated documentation, and digital follow-up while minimizing disruption to physicians and staff; and AllergiEnd, a diagnostic and allergen immunotherapy system for the busy non-allergist in a primary care setting. Its products are designed to promote prevention, early detection, management, and reversal of chronic diseases. The company was formerly known as USA Equities Corp. and changed its name to QHSLab, Inc. in April 2022. The company was incorporated in 1983 and is based in West Palm Beach, Florida.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
USA Equities Corp is a small-cap issuer quoted on the OTCQB for which publicly available corporate descriptions and recent filings are limited, so its core business and operations are not clearly documented. Long-term growth drivers cannot be confirmed from public records; the company may benefit if management executes asset acquisitions, improves disclosure and demonstrates sustainable revenue generation.
Principal risks include low liquidity and thin trading on the OTC market, potential equity dilution, limited audited financial information, and execution or governance risk that could materially affect shareholder value—investors should monitor regulatory filings and company announcements.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 0.46M | -0.26M | -0.47M | -1.00M | -0.77M |
| Net income | 0.46M | -0.26M | -0.47M | -1.00M | -0.77M |
| Selling general administrative | 1.12M | 0.79M | 0.75M | 0.92M | 1.05M |
| Gross profit | 1.81M | 1.36M | 0.79M | 0.62M | 0.67M |
| Reconciled depreciation | 0.09M | 0.15M | 0.15M | 0.13M | 0.04M |
| Ebit | - | - | - | -0.56M | -0.50M |
| Ebitda | - | - | - | -0.43M | -0.49M |
| Operating income | 0.13M | 0.21M | -0.24M | -0.56M | -0.50M |
| Interest expense | 0.24M | 0.47M | 0.23M | 0.43M | 0.25M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Net interest income | -0.24M | -0.47M | -0.23M | -0.43M | -0.25M |
| Total revenue | 2.69M | 2.13M | 1.41M | 1.24M | 1.41M |
| Total operating expenses | 2.56M | 1.93M | 1.65M | 1.80M | 1.92M |
| Cost of revenue | 0.88M | 0.77M | 0.62M | 0.62M | 0.74M |
| Total other income expense net | 0.56M | 0.00M | 0.00M | -0.00M | -0.02M |
| Net income from continuing ops | 0.46M | -0.26M | -0.47M | -1.00M | -0.77M |
| Net income applicable to common shares | - | - | - | -1.00M | -0.77M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 2.17M | 1.80M | 1.68M | 1.96M | 2.21M |
| Intangible assets | 1.29M | 1.38M | 1.53M | 1.67M | 1.76M |
| Other current assets | 0.02M | 0.03M | 0.01M | 0.01M | 0.02M |
| Total liab | 0.55M | 2.41M | 2.06M | 1.88M | 1.38M |
| Total stockholder equity | 1.62M | -0.61M | -0.38M | 0.08M | 0.82M |
| Other current liab | 0.02M | 0.34M | 0.20M | 0.12M | 0.06M |
| Common stock | - | - | - | 0.00M | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -3.90M | -4.33M | -3.98M | -3.51M | -2.52M |
| Other liab | - | - | - | - | 0.01M |
| Cash | 0.64M | 0.16M | 0.05M | 0.18M | 0.29M |
| Total current liabilities | 0.45M | 2.41M | 2.06M | 1.71M | 0.87M |
| Net debt | - | 1.57M | 1.73M | 1.50M | 1.01M |
| Short long term debt | 0.11M | 1.72M | 1.78M | 1.50M | 0.80M |
| Other stockholder equity | - | - | - | - | -0.01M |
| Total current assets | 0.88M | 0.42M | 0.16M | 0.29M | 0.45M |
| Net tangible assets | - | - | - | -1.60M | -0.94M |
| Net receivables | 0.19M | 0.20M | 0.07M | 0.05M | 0.07M |
| Long term debt | 0.10M | - | - | 0.17M | 0.50M |
| Inventory | 0.04M | 0.04M | 0.03M | 0.05M | 0.07M |
| Accounts payable | 0.33M | 0.34M | 0.08M | 0.09M | 0.02M |
| Non current assets total | 1.29M | 1.38M | 1.53M | 1.67M | 1.76M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | - | 0.00M | -0.04M | -0.15M |
| Change to liabilities | - | - | - | 0.07M | -0.13M |
| Total cashflows from investing activities | - | - | - | -0.04M | -0.15M |
| Net borrowings | -0.20M | -0.04M | 0.03M | 0.26M | 0.76M |
| Total cash from financing activities | 0.30M | -0.04M | 0.03M | 0.28M | 0.70M |
| Change to operating activities | - | - | - | 0.07M | 0.07M |
| Net income | 0.46M | -0.26M | -0.47M | -1.00M | -0.77M |
| Change in cash | 0.48M | 0.11M | -0.13M | -0.11M | 0.19M |
| Begin period cash flow | 0.16M | 0.05M | 0.18M | 0.29M | 0.09M |
| End period cash flow | 0.64M | 0.16M | 0.05M | 0.18M | 0.29M |
| Total cash from operating activities | 0.18M | 0.14M | -0.16M | -0.35M | -0.35M |
| Issuance of capital stock | 0.50M | 0.00M | 0.00M | 0.05M | 0.03M |
| Depreciation | 0.09M | 0.15M | 0.15M | 0.13M | 0.04M |
| Change to inventory | 0.01M | -0.02M | 0.03M | 0.01M | 0.03M |
| Change to account receivables | -0.00M | -0.13M | -0.03M | 0.01M | -0.01M |
| Other cashflows from financing activities | - | - | - | -0.03M | -0.09M |
| Change to netincome | - | - | - | 0.05M | 0.26M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.04M | 0.15M |
| Change in working capital | 0.17M | 0.24M | 0.06M | 0.16M | -0.03M |
| Stock based compensation | - | 0.00M | 0.01M | 0.03M | 0.04M |
| Other non cash items | 0.50M | 0.02M | 0.08M | 0.31M | 0.35M |
| Free cash flow | 0.18M | 0.14M | -0.16M | -0.39M | -0.51M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| USAQ USA Equities Corp |
-0.06 23.58% |
0.21 | 10.00 | 17.24 | 1.99 | 3.09 | 1.49 | 6.24 |
| ABT Abbott Laboratories |
- -% |
104.48 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
-1.43 1.40% |
100.89 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
0.19 0.06% |
318.15 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
-0.10 0.22% |
47.50 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
QHSLab, Inc., a medical device technology and software-as-a-service (SaaS) company, provides tools to evaluate and treat chronic disease and preventive care through reimbursable procedures. The company focuses on value-based healthcare, informatics, and algorithmic personalized medicine, including digital therapeutics, behavior based remote patient monitoring, and chronic care and preventive medicine. Its digital healthcare and clinical decision support and point of care solutions also support non face to face remote patient and therapeutic monitoring, address chronic care, and preventive medicine. The company provides quality health system lab expert system (QHSLab), designed to function as an extension of a medical practice's existing clinical workflow that supports structured screening, automated documentation, and digital follow-up while minimizing disruption to physicians and staff; and AllergiEnd, a diagnostic and allergen immunotherapy system for the busy non-allergist in a primary care setting. Its products are designed to promote prevention, early detection, management, and reversal of chronic diseases. The company was formerly known as USA Equities Corp. and changed its name to QHSLab, Inc. in April 2022. The company was incorporated in 1983 and is based in West Palm Beach, Florida.
901 Northpoint Parkway, West Palm Beach, FL, United States, 33407
929 379 6503
12
| Name | Title | Year Born |
|---|---|---|
| Mr. Troy James Grogan | CEO, CFO, Pres & Chairman | 1977 |
| Ms. Cyndi Cole CPA, M.B.A. | Financial Controller | NA |
| Olivia Giamanco | Marketing Director | NA |
| Mr. Troy James Grogan | CEO, CFO, President & Chairman | 1977 |
| Ms. Olivia Giamanco | Marketing Director | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.